Table 2 Prescription and cost of the studied drugs at 1, 6, and 18 months after the intervention
Intervention (n = 120) | Control (n = 119) | p | |
|---|---|---|---|
Omeprazole, % (95%CI)* | |||
+ 1 month | 46.86 (44.34–49.39) | 47.36 (44.81–49.91) | 0.744 |
+ 6 months | 48.02 (45.58–50.46) | 47.90 (45.01–50.79) | 0.696 |
+ 18 months (primary outcome) | 46.28 (43.77–48.79) | 47.15 (44.39–49.91) | 0.971 |
COX-2 inhibitors, % (95%CI)¶ | |||
+ 1 month | 11.70 (9.83–13.57) | 15.38 (12.87–17.90) | 0.131 |
+ 6 months | 11.59 (9.28–13.89) | 15.74 (13.42–18.05) | 0.061 |
+ 18 months (primary outcome) | 12.07 (9.75–14.41) | 13.08 (10.75–15.41) | 0.085 |
Clopidogrel, DDD/1000 (95%CI) | |||
+ 1 month | 0.098 (0.886–0.107) | 0.103 (0.094–0.112) | 0.456 |
+ 6 months | 0.090 (0.082–0.098) | 0.099 (0.089–0.108) | 0.230 |
+ 18 months | 0.091 (0.083–0.100) | 0.091 (0.082–0.100) | 0.840 |
Cost 1–18 m/1000, € (95%CI)¶ | |||
Gastric secretion modifiers | 1647.79 (1541.37–1754.21) | 1626.38 (1511.76–1741.01) | 0.880 |
NSAIDs | 1099.26 (984.70–1213.81) | 983.02 (873.49–1092.55) | 0.515 |
Clopidogrel | 476.45 (428.34–524.57) | 539.05 (491.22–586.87) | 0.184 |
Total | 3223.50 (2999.55–3447.44) | 3143.92 (2917.61–3370.23) | 0.848 |